Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -7.75% is 179% below its 5-year average of 9.76%, near the low end of its 5-year range (-13.59%–39.68%).
82.57% below its 12-month average of -4.25%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -2.71%.
RETURN ON ASSETS (ROA)
-7.75%
RETURN ON ASSETS (ROA) AVG TTM
-4.25%
RETURN ON ASSETS (ROA) AVG 3Y
-2.93%
RETURN ON ASSETS (ROA) AVG 5Y
9.76%
RETURN ON ASSETS (ROA) AVG 10Y
-9.84%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-82.57%
CURRENT VS 3Y AVG
-164.28%
CURRENT VS 5Y AVG
-179.42%
CURRENT VS 10Y AVG
+21.27%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-24.96%
median of 441 covered companies
CURRENT VS SECTOR MEDIAN
+68.95%
vs the sector median at left
Fulgent Genetics, Inc.
Market Cap
$637.59M
Return on Assets (ROA)
-7.75%
TTM Avg
-4.25%
3Y Avg
-2.93%
5Y Avg
9.76%
Market Cap
$642.31M
Return on Assets (ROA)
-13.75%
TTM Avg
-12.94%
3Y Avg
-23.44%
5Y Avg
-17.36%
Market Cap
$632.76M
Return on Assets (ROA)
-23.40%
TTM Avg
-34.85%
3Y Avg
-33.75%
5Y Avg
-41.05%
Market Cap
$643.37M
Return on Assets (ROA)
-37.63%
TTM Avg
-55.16%
3Y Avg
-41.63%
5Y Avg
-48.17%
Market Cap
$675.41M
Return on Assets (ROA)
-36.37%
TTM Avg
-26.71%
3Y Avg
-31.04%
5Y Avg
-27.33%
Market Cap
$596.36M
Return on Assets (ROA)
-42.15%
TTM Avg
-50.20%
3Y Avg
-44.84%
5Y Avg
-47.93%
Market Cap
$688.14M
Return on Assets (ROA)
-82.36%
TTM Avg
-56.97%
3Y Avg
-52.21%
5Y Avg
-45.34%
Market Cap
$579.88M
Return on Assets (ROA)
-37.16%
TTM Avg
-32.95%
3Y Avg
-32.95%
5Y Avg
-32.95%
Market Cap
$698.60M
Return on Assets (ROA)
-103.29%
TTM Avg
-79.28%
3Y Avg
-61.36%
5Y Avg
-60.54%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Fulgent Genetics, Inc. (FLGT) | $637.59M | -7.75% | -4.25% | -2.93% | 9.76% |
| AngioDynamics, Inc. (ANGO)vs › | $642.31M | -13.75% | -12.94% | -23.44% | -17.36% |
| Climb Bio, Inc. (CLYM)vs › | $632.76M | -23.40% | -34.85% | -33.75% | -41.05% |
| Aura Biosciences, Inc. (AURA)vs › | $643.37M | -37.63% | -55.16% | -41.63% | -48.17% |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $675.41M | -36.37% | -26.71% | -31.04% | -27.33% |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $596.36M | -42.15% | -50.20% | -44.84% | -47.93% |
| Annexon, Inc. (ANNX)vs › | $688.14M | -82.36% | -56.97% | -52.21% | -45.34% |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $579.88M | -37.16% | -32.95% | -32.95% | -32.95% |
| Faeth Therapeutics, Inc. (FTH)vs › | $698.60M | -103.29% | -79.28% | -61.36% | -60.54% |
| Aquestive Therapeutics, Inc. (AQST)vs › | $573.38M | -59.22% | -47.88% | -51.20% | -67.88% |
ROA
-7.8%
ROE
-8.4%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -4.99% |
| 2024-12-31 | -3.50% |
| 2023-12-31 | -13.59% |
| 2022-12-31 | 10.35% |
| 2021-12-31 | 39.68% |
| 2020-12-31 | 30.60% |
| 2019-12-31 | -0.46% |
| 2018-12-31 | -10.19% |
| 2017-12-31 | -4.41% |
| 2016-12-31 | -9.21% |
| 2015-12-31 | -142.56% |
| 2014-12-31 | -202.03% |
